Multiplex genotyping of CYP3A4, CYP3A5, CYP2C9 and CYP2C19 SNPs using MALDI-TOF mass spectrometry

被引:4
作者
Falzoi, Matteo [1 ]
Mossa, Alessandra [2 ]
Congeddu, Elena [2 ]
Saba, Luisella [2 ]
Pani, Luca [1 ,2 ,3 ]
机构
[1] CNR, ITB, I-09010 Pula, CA, Italy
[2] PharmaNess SCARL, I-09010 Pula, CA, Italy
[3] Consorzio Pharma GEN, I-09010 Pula, CA, Italy
关键词
CYP2C9; CYP2C19; CYP3A4; CYP3A5; CYP450; drug treatment; individualized therapy; mass spectrometry; pharmacogenetics; GENETIC POLYMORPHISMS; DRUG-THERAPY; PHARMACOGENETICS; CYTOCHROME-P450; METABOLISM;
D O I
10.2217/PGS.09.172
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Background: Pharmacogenetics is the study of genetic variations that cause alterations in drug level, drug response and adverse drug reactions. SNPs found in CYP450 genes have the greatest genetic influences on interindividual variability in drug bioavailability. The polymorphic nature of these genes may modulate several enzyme levels that affect individual responses to pharmacological treatment. Among them, CYP3A4, CYP3A5, CYP2C9 and CYP2C19 isoforms of CYP450 enzymes are involved in the metabolism of many commonly prescribed drugs. Aims: In this study, we would like to develop a CYP450 genotyping platform that could lead a complete definition of a patient's metabolic genotype in order to improve the clinical outcome of some drug treatments. Materials & methods: We used matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) (Sequenom (R)) to develop a SNP genotyping method. Results: This MALDI-TOF-based multiplexing system allows the simultaneous and efficient genotyping of a set of CYP450 gene polymorphisms. Conclusion: The multiple CYP450 gene testing achieved with this application can be used to develop diagnostic tests to predict drug responses and clinical outcomes.
引用
收藏
页码:559 / 571
页数:13
相关论文
共 16 条
[1]
Pharmacogenomics and individualized drug therapy [J].
Eichelbaum, M ;
Ingelman-Sundberg, M ;
Evans, WE .
ANNUAL REVIEW OF MEDICINE, 2006, 57 :119-137
[2]
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily [J].
Goldstein, JA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (04) :349-355
[3]
Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity [J].
Ingelman-Sundberg, M .
PHARMACOGENOMICS JOURNAL, 2005, 5 (01) :6-13
[4]
Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future [J].
Ingelman-Sundberg, M .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (04) :193-200
[5]
Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects [J].
Ingelman-Sundberg, Magnus ;
Sim, Sarah C. ;
Gomez, Alvin ;
Rodriguez-Antona, Cristina .
PHARMACOLOGY & THERAPEUTICS, 2007, 116 (03) :496-526
[6]
Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes [J].
Kirchheiner, Julia ;
Seeringer, Angela .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2007, 1770 (03) :489-494
[7]
Genetic contribution to variable human CYP3A-mediated metabolism [J].
Lamba, JK ;
Lin, YS ;
Schuetz, EG ;
Thummel, KE .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (10) :1271-1294
[8]
Single nucleotide polymorphism detection:: allelic discrimination using TaqMan [J].
McGuigan, FEA ;
Ralston, SH .
PSYCHIATRIC GENETICS, 2002, 12 (03) :133-136
[9]
Matrix-assisted laser desorption/ionisation, time-of-flight mass spectrometry in genomics research [J].
Ragoussis, Jiannis ;
Elvidge, Gareth P. ;
Kaur, Kulvinder ;
Colella, Stefano .
PLOS GENETICS, 2006, 2 (07) :920-929
[10]
Ragoussis Jiannis, 2006, Drug Discov Today Technol, V3, P115, DOI 10.1016/j.ddtec.2006.06.013